Fig. 3.

Mean days between each intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection over time. *The overall mean days between each injection, weighted per number of patients receiving each subsequent injection, were 42.4 for aflibercept patients and 40.6 for ranibizumab patients, a difference of 1.8 days (95% CI 1.3–2.3). Red dashed lines drawn at 30 and 60 days represent the expected time between aflibercept injections based on package insert: once-monthly for the first 3 months followed by once every other month for aflibercept. Error bars represent one standard deviation. To increase sample size, this analysis was conducted among all study-eligible patients regardless of having any minimum duration of available follow-up. The number of contributing patients for calculations were—1 to 2: Aflibercept (A) = 570, Ranibizumab (R) = 1 502; 2–3: A = 418, R = 1 173; 3–4: A = 270, R = 859; 4–5: A = 178, R = 622; 5–6: A = 95, R = 455; 6–7: A = 57, R = 319; 7–8: A = 33, R = 234; 8–9: A = 20, R = 161; 9–10: A = 15, R = 116; 10 +: A = 7, R = 75